
FIGURE 1


ALLEGRO:
N = 1106 patients randomized
n= 550 patients assigned to oral laquinimod (LAQ) 0·6 mg daily
n = 556 patients assigned to oral placebo (PBO)
939 patients with at least 1 valid scheduled post-baseline MRI assessment
n = 478 LAQ WM and GM fraction
n = 461 PBO WM and GM fraction
n = 476* LAQ Thalamic fraction
n = 458* PBO Thalamic fraction
n = 251 LAQ Thalamic lesions at baseline
n = 234 PBO Thalamic lesions at baseline
n = 238 LAQ Thalamic lesions at baseline and MRI scan at 12 or 24 months
Sub-studies
n = 214 PBO Thalamic lesions at baseline and MRI scan at 12 or 24 months
"Frequent MRI" Cohort N = 386 from 58 sites
MT MRI Cohort N = 92 from 10 sites
^{1}H-MRS Cohort N = 28 patients from 6 sites n=27 patients with evaluable data at baseline and at 24 months
n = 149 LAQ
n = 157 PBO
n = 45 LAQ
n = 47 PBO
n = 12 LAQ
n = 15 PBO
n = 124 patients with active lesions at baseline or during the study for PBH analysis
n = 75 patients evaluable at baseline and at 12 months
n = 55 LAQ
n = 69 PBO
n = 38 LAQ
n = 37 PBO
n = 63 patients evaluable at baseline and at 24 months and at 12 and 24 months
n = 31 LAQ
n = 32 PBO